| Name | Title | Contact Details |
|---|---|---|
Alan Smith |
Chief Technology Officer | Profile |
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.
Providing Cold Chain Storage Solutions to Military, EMS, and Hospital. Mobile Blood Banks, vaccines and pharmaceuticals.
BioTech Insight is a Pebble Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.